Background: Green tea polyphenols (GTP) are known to have several health benefi ts. In spite of these benefi ts, its application as a therapeutic agent is limited due to some of its limitations such as stability, bioavailability, and biotransformation. To overcome these limitations, liposomal nanoparticles have been used as a carrier of the GTP. Objective: Encapsulation of GTP to the liposomal nanoparticles in order to achieve a sustained release of the GTP and to determine the drug release kinetics and the mechanism of the release. Materials and Methods: GTP encapsulated liposomal nanoparticles were prepared using phosphatidyl choline and cholesterol. The synthesized particles were characterized for their particle size and morphology. In vitro release studies were carried out, followed by drug release kinetics, and determining the mechanism of release. In vitro, antioxidant assay was determined following 2,2-diphenyl-1-picrylhydrazyl (DPPH) method. Results: Atomic force microscope (AFM) and high resolution scanning electron microscope (HR SEM) images showed spherical particles of the size of 64.5 and 252 nm. An encapsulation effi ciency as high as 77.7% was observed with GTP concentration of 5 mg.mL -1 . In vitro release studies showed that the loading concentrations of GTP were independent to the cumulative percentage of the drug release. GTP release by varying the pH and temperature showed a direct correlation between the release parameter and the percentage of drug release. The higher the pH and temperature, the higher was the percentage of the drug release. The release data showed a good correlation with Zero order kinetics and the mechanism of the release being anomalous mode. Radical scavenging activity of the released GTP showed a potent scavenging activity. Conclusion: GTP encapsulated liposomal nanoparticles could be used as a delivery vehicle for achieving a sustained release.
Background
Liposomes are considered to be an ideal drug carrier as they consist of an aqueous core encapsulated by the natural or synthetic phospholipids and can deliver both hydrophobic and hydrophilic drugs. Hydrophobic drugs are likely to be entrapped within the lipid bilayer, while the hydrophilic drugs have a tendency to be entrapped within the core (1) . Several liposomal formulations have been approved for delivery of the drugs like amphotericin B (2), doxorubicin (3), vincristine sulfate (4), cytarabine (5), etc. Few of the recent advancements in the liposomal nanoparticles based drug delivery system include the work of Ong et al. (6) , where liposomal ciprofl oxacin have been explored to predict the enhanced lung residence time of the formulation. Zhou et al. (2015) developed a novel liposomal formulation for the cisplatin to study the potent antitumor activity in vitro and in vivo and achieved signifi cantly decreased the incidence of the side eff ects with cisplatin loaded liposomal nanoparticles than that of free cisplatin (7) .
The green tea polyphenols (GTP) are known to have a wide range of health benefi ts. The major constituents of the tea polyphenols, known as catechins constitute about 30-42% of the dry weight (8) . Several reports are available on the applications of GTP in the preventive eff ects of cancer (9) , cardiovascular diseases (10) , and neuroprotective eff ects (11) . In spite of several health benefi ts, its use as a therapeutic agent is limited due to a few limitations such as bioavailability, stability,
Materials and Methods
The green tea polyphenols (GTP) was purchased from the Sigma Chemical Co., USA. Other chemicals such as cholesterol, phosphatidylcholine, and tween 80 were procured from Himedia, India.
Synthesis of the GTP Loaded Liposomal Nanoparticles
Phosphatidyl choline and cholesterol in a ratio of 20:1 was dissolved in 2 mL ethanol to form a lipid phase. This mixture was heated in a water bath at 60 °C. Tween 80 (0.1%) was dissolved in 10 mL PBS (pH 6.5) to form an aqueous phase. The obtained aqueous phase was dropped into lipid phase upon stirring. The mixture was placed on a magnetic stirrer for 10 min followed by sonication at 30% amplifi cation for 10 min. The fi nal liposomal nanoparticles were obtained after being cooled in the ice bath, diluted to 20 mL, and fi ltered. For GTP loaded liposomal nanoparticles, diff erent quantities (1, 2.5, 5 and 10 mg) of the GTP were dissolved in 1 mL ethanol prior to the dissolution of the phosphatidyl choline and cholesterol (14) .
Characterization of Liposomal Nanoparticles
The hydrodynamic diameter and the surface charge of the nanoparticles were determined by dynamic light scattering (DLS) and ζ potential analysis using Nanopartica, Nanoparticle analyzer SZ-100. The morphology and polydispersity of the particles were analyzed through atomic force microscope (AFM, Nano Surf Easy Scan2, Switzerland) and high resolution scanning electron microscope (HR SEM, FEI Quanta FEG 200).
Determination of Encapsulation Effi ciency (EE)
The encapsulation effi ciency was determined by separating the unloaded GTP by centrifugation. The amount of unloaded GTP was quantifi ed by photometric Folin-Ciocalteu assay as described by Swain and Hillis (15) . About 0.5 mL of sample was added to 0.5 mL of 1 M Follin -Ciocalteu reagent and 0.5 mL of 35% sodium carbonate. The mixture was incubated for 30 min in dark and the absorbance was measured at 700 nm applying a spectrophotometer. EE was calculated using the formula: 
Release of GTP from the Liposomal Nanoparticles
Release studies were carried out in the phosphate buff er saline (PBS) at a physiological pH of 7.4 at 37 °C through dialysis method. One mL of the encapsulated GTP nanoparticles was transferred to a dialysis bag with both ends sealed. The bag was placed in a beaker containing 50 mL of PBS. At appropriate time intervals (1, 2, 3, 4, 5, 6, 7, 8, 12, 24 , and 48 h), 1 mL of the sample from the beaker was withdrawn. The collected samples were used to determine the amount of drug released. Quantifi cation of the GTP was carried out by the method developed earlier (15) . The drug release profi les were studied for the diff erent loading concentrations of GTP (1, 2.5, 5, and 10 mg.mL -1 ) at diff erent pH (3, 7.4, and 9) and temperatures (room temperature (RT), at 37 and 45 °C, respectively).
In vitro Antioxidant Assay
The radical scavenging activity of the released GTP was determined in vitro by 1, 1-diphenyl-2-picrylhydrazyl (DPPH) assay following the method of Williams et al. (16) . About 0.1 mM DPPH was used for the study and was prepared in the absolute ethanol. To 0.5 mL of DPPH, 100 μL of the sample and 550 μL PBS was added. The mixture was incubated for 30 min in dark and the absorbance was measured at 517 nm using a spectrophotometer.
Mathematical Modelling
In vitro release data was fi tted to various mathematical models to study the drug release kinetics and the mechanism of the drug release was studied as well.. The diff erent models that were used in this study are Zero order, First order, Higuchi, Hixson-Crowell and Korsemeyer-Peppas models (17) . The correlation coeffi cient (R 2 ) and the release exponent (n) were used to determine the best-fi t kinetic model and the mechanism of the drug release.
Statistical Analysis
All the data were subjected to the analysis of variance (ANOVA) and presented as mean ± SD. The means were separated by Duncan's multiple range test (DMRT) at p ≤0.05. 
Results
GTP at diff erent concentrations was encapsulated into the liposomal nanoparticles. The mean hydrodynamic diameter of the particles was observed to be 322.1 nm with a polydispersity index of 0.921. The AFM and HR SEM images revealed spherical particles with sizes of 64.5 and 252 nm, respectively (Fig. 1) . The particles were negatively charged with a zeta potential value of -24.2 ± 2.75 mV.
The encapsulation effi ciency (EE) of the GTP loaded liposomal nanoparticles are presented in Table 1 . The maximum EE (77.78%) was observed when GTP was loaded at a concentration of 5 mg.mL -1 .
In vitro drug release of the GTP from liposomal nanoparticles were studied at diff erent concentrations of the GTP (1, 2.5, 5, and 10 mg.mL -1 ), at diff erent pH (3, 7.4, and 9), and temperatures (RT, 37 °C, and 45 °C) (Fig. 2) . At a GTP concentration of 1 mg.mL -1 , 68% of the drug was released during the initial 8 h, and as the release was prolonged up to 48 h, 78% of the drug was released. With the increase in the concentration of GTP in the liposomal nanoparticles, the cumulative percentage of drug release decreased (61% and 60% was observed for 2.5 and 5 mg.mL -1 respectively in 48 h). No signifi cant diff erence was observed in the release pattern for 2.5 and 5 mg.mL -1 of the loaded GTP. As , a signifi cant increase in the cumulative percentage of the drug release was observed, where 83% of the drug was released in 48 h. The release of GTP was monitored by varying pH of the release medium. It was observed that, as pH of the medium shifted from acidic to basic, there was an increase in the cumulative percentage of the drug release. About 50% of the drug was released at pH 3 in 48 h, while at pH 7.4 and 9 it was 60 and 74%, respectively. As the temperature was increased from RT to 45 °C, an increase in the cumulative percentage of the drug release was observed. At RT, about 53% of the drug was released within 48 h. As the temperature was increased to 37 °C and 45 °C, 60% and 79% of the drug was released within 48 h.
The obtained in vitro release data was fi tted to various kinetic models. The regression parameters (i.e., the regression coeffi cients (R 2 )), the release kinetic constants (k), and the release exponent (n) are presented in Table 2 for the diff erent parameters. All the release data showed a good correlation with Zero order kinetics. Predominance was observed in the anomalous mode of the drug transport, as the release exponent (n) for all the release data were observed to be in the range of 0.43-0.89. The release mechanism here is characterized by coupling of the diff usion and erosion mechanisms.
All the released samples showed potent antioxidant activities. The free radical scavenging activity of GTP loaded liposomal nanoparticles is shown in Figure  3 . The highest scavenging activity was observed to be 75% for GTP concentration of 10 mg.mL -1 for the sample released in 7 h, while the activity was observed to be 72% for the GTP concentration of 5 mg.mL -1 No signifi cant diff erence in the activity was observed for the GTP concentrations of 2.5 and 1 mg.mL -1 .
Discussion
Several studies have been carried out using liposomes for the drug delivery to the target cancer (18) (19) (20) , for the treatment of the Alzheimer's disease (21), and various biomedical fi elds including immunoassay and targeted drug delivery (22) . To the best of our knowledge, there are no articles available on the encapsulation of GTP to liposomal nanoparticles. Our work emphasizes on the encapsulation of the GTP to liposomal nanoparticles and developing a sustained release system. Liposomal nanoparticles have been synthesized and the results of our study showed particles with a diameter of ~250 nm. As well, the particles are being stable (ζ potential value of -24.2 ± 2.75 mV), while Wang et al. (23) have reported the surface charge of the liposomal nanoparticles to be -15 mV. The high ζ potential (positive or negative) provides a good dispersion stability by preventing aggregation and fusion of the liposomes due to electrostatic repulsion (24) . The DLS results showed a higher hydrodynamic diameter of the particles compared to that of AFM and HR SEM (64.5 and 252 nm, respectively). The higher size of the particles could be due to the aggregation of the particles within the dispersion medium.
To enhance the effi ciency of the GTP, liposomal nanoparticles were used as carriers. Upon loading diff erent concentrations of the GTP to the liposomal nanoparticles, with an increased concentration of the GTP up to 5 mg.mL -1 , there was an increase in the EE and on further increasing, the GTP concentration, EE was decreased (Table 1) . Therefore, 5 mg.mL -1 GTP was considered as an optimal loading concentration where EE was 77.7%, while Ramasamy et al. (2014) have reported the EE of MTX hydrochloride to the liposomal nanoparticles to be ~60% (25) . Analyzing the release pattern, by applying diff erent loaded concentrations of the GTP showed no particular trend in the cumulative percentage of the drug release. The pH of the release medium was shown to play a role in the release of GTP from liposomal nanoparticles. A maximum of 60% of the GTP was released in 48 h at a pH of 7.4. In a similar study carried out by Ramasamy et al. (25) , a maximum of 80% of the drug was released from the liposomal nanoparticles in 48 h when the release was carried out at pH 7.4. As the release medium shifted from acidic to basic, there was an increase in the cumulative percentage of the drug release. One of the limitations for the orally developed formulations is its metabolism in the gastrointestinal tract (GIT) which is mostly due to the harsh pH conditions of the GIT. In our study, to simulate the conditions of GIT, the release was carried out in a medium with acidic pH (pH 3). In an acidic pH (pH 3), a lower percentage of the drug was released, while the maximum drug was retained within the nanoparticles. In basic pH (pH 9), the percentage of drug release was increased. The basic pH might have aff ected the structure or the complexity of the liposomes, thereby releasing more amount of the drug. The temperature of release medium was directly proportional to the cumulative percentage of the drug release. As the temperature was increased, there was an increase in the drug release percentage. The higher temperatures could infl uence the structure of the liposomal nanoparticles or may aff ect the binding between liposomes and GTP thereby releasing a higher percentage of the drug (Fig. 2) .
In vitro, drug release data was fi tted into various kinetics models to evaluate the drug release mechanism ( Table 2 ). The ideal model of the drug release for nanoparticulate dosage forms or sustained release formulations is the Zero order kinetics (17) . All our release data showed good correlation with Zero order kinetics, therefore, liposomal nanoparticles could be used as an ideal carrier for the delivery of GTP, achieving a prolonged or a sustained release. Korsmeyer-Peppas stated that for a Fickian release, n value is constrained to 0.5, 0.45, and 0.43 for the release from slabs, cylinders, and spheres (26) . For spheres, values of n ranging from 0.43-0.89 are regarded as anomalous and the release is characterized by diff usion and erosion mechanism and that > 0.89 is characterized by the polymer erosion and relaxation and is termed as super case II transport. In our study, n values ≤ 0.43 was regarded as a pure Fickian release, as the release of GTP was from spherical nanoparticles and the release was through diff usion. Predominance in anomalous transport was observed, which involves a coupling of erosion and diff usion.
Antioxidant assay revealed the potent scavenging Upputuri RTP & Mandal AKA activity of the GTP with respect to the released GTP at various times (Fig. 3) . It has proved the retention of the antioxidant activity of GTP even after release from the liposomal nanoparticles. The highest scavenging activity was observed between 5-7 h which corresponds to the higher amounts of drug released. The potent scavenging activity was observed for all the released samples and GTP encapsulated liposomal nanoparticles could be used as an eff ective antioxidant source. To conclude, for achieving a prolonged release of the GTP, 5 mg.mL -1 loading concentration was ideal in the acidic pH at 37 C. The in vitro release data showed a good correlation of the GTP released with the release parameters such as pH and temperature, suitable for an ideal oral formulation where the release was minimum in the lower pH and temperature. The predominance was observed in Zero order kinetics with anomalous mode of transport. The antioxidant potential was observed for all the released samples. On further evaluation, the GTP encapsulated liposomal nanoparticles would serve as a potent source for oral delivery.
